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Background: Increases in interleukin 6 (IL-6) and agonistic autoantibodies to the angiotensin II 
type 1 receptor (AT1-AA) are proposed to be important links between placental ischemia and 
hypertension in preeclampsia.
Methods: The purpose of this study was to determine whether IL-6 (5 ng/day), infused into 
normal pregnant (NP) rats, increased mean arterial pressure (MAP) and AT1-AA. MAP was 
analyzed in the presence and absence of an angiotensin type 1 receptor (AT1R) antagonist, 
losartan, L.
Results: MAP and AT1-AA increased from102 ± 2 to 118 ± 4 mmHg and 0.7 ± 0.3 NP to 
14.1 ± 1.4 chronotropic units with chronic IL-6 infusion. MAP responses to IL-6 were abolished 
in losartan pretreated rats (85 ± 4 in NP + L vs 85 ± 3 mmHg in IL-6 + L).
Conclusion: These data indicate that IL-6 stimulates AT1-AA and that activation of the AT1R 
mediates IL-6 induced hypertension during pregnancy.
Keywords: cytokines, pregnancy, hypertension, renin angiotensin system, inflammation
Introduction
Preeclampsia occurs in at least 5%–8% of all pregnancies, and is defined as new onset 
hypertension with proteinuria during pregnancy.1,2 Typically, preeclampsia occurs 
after 20 weeks gestation (in the late 2nd or 3rd trimesters or middle to late pregnancy). 
While preeclampsia and other hypertensive disorders of pregnancy are a leading 
cause of maternal and infant illness and death, responsible for 76,000 maternal and 
500,000 infant deaths each year, the underlying physiological mechanisms involved 
in pathogenesis of this disease remains to be fully elucidated.1–5
Recent data from our laboratory has shown that elevations in inflammatory 
cytokines, such as TNF alpha, interleukin-6 and activation of immune cells such as 
monocytes, macrophages and both T and B lymphocytes, and autoantibody generation 
play an important role in the pathogenesis of hypertension in response to reductions 
in uterine perfusion pressure.4–9 Recent obstetrical studies indicate that preeclamptic 
women exhibit high levels of agonistic autoantibodies to the angiotensin II type I recep-
tor (AT1-AA).10–12 These AT1-AA bind to and activate the AT1R and result in many of 
the same signaling processes as angiotensin II. Recent studies from the Xia laboratory 
indicate that the severity of preeclampsia strongly correlates with levels of AT1-AA.13 
Our most recent proof of concept studies have demonstrated an important role for these 
AT1-AA in the pathogenesis of hypertension in a rat model of preeclampsia.6,14–16 We 
have shown that chronic infusion of rat AT1-AA activate many systems suspected of 
playing an important role in the pathogenesis of preeclampsia, such as endothelin-1, 
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reactive oxygen species, and sFlt-1 and S-endoglin during 
pregnancy.14–16 Although many studies have shown the 
importance of AT1-AA in mediating the pathophysiology 
associated with preeclampsia, the antigen eliciting production 
of the autoantibody remains unknown.
We reported that reductions in uterine perfusion pressure 
(RUPP) in pregnant rats is a stimulus for the AT1-AA.5,6 We 
have also shown increased TNF alpha and IL-6 in response 
to RUPP in pregnant rats.4–6 We have further demonstrated 
a role for TNF alpha in mediating hypertension during preg-
nancy by activating both the endothelin system and by serving 
as a stimulus for production of AT1-AA in pregnant rats.4–6 
Similar to RUPP rats, TNF alpha-induced hypertension is 
blunted in the presence of AT1 receptor blockade. These 
studies suggest a role for activation of the AT1 receptor, 
possibly via the AT1-AA, in mediating hypertension during 
pregnancy burdened by either elevated circulating TNF alpha 
or reduced uterine perfusion pressure.
In defining a role for IL-6 in mediating hypertension dur-
ing pregnancy, we recently demonstrated that a three-fold 
increase in circulating IL-6, to levels comparable to RUPP 
rats, in normal pregnant rats significantly raised mean arte-
rial pressure.8 In that study, we further demonstrated a role 
for IL-6 to decrease renal pressure natriuresis and stimulate 
plasma renin activity in pregnant rats while having no 
effect in virgin rats. While IL-6 and AT1-AA are elevated 
in response to placental ischemia and in women with preec-
lampsia, it is unknown whether IL-6, like TNF alpha, may 
serve as an important stimulus for the production of AT-AA 
during pregnancy. Moreover, it is unknown whether the 
hypertension associated with chronic increases in plasma 
IL-6 in pregnant rats is dependent upon activation of the 
angiotensin type 1 receptor. Therefore, with this study, we 
have repeated our IL-6 induced hypertensive pregnant rat 
model with the purpose of investigating a role for IL-6 as a 
potential stimulus for AT1-AA. A second aim of the study 
was to determine a role for activation of AT1-receptors, pos-
sibly via the AT1-AA, in mediating IL-6-induced hyperten-
sion during pregnancy.
Methods
All studies were performed in age-matched, timed preg-
nant Sprague Dawley rats purchased from Harlan Sprague 
Dawley Inc (Indianapolis, IN). Animals were housed in a 
temperature-controlled room (23°C) with a 12:12 hour light/
dark cycle. All experimental procedures executed in this 
study were in accordance with National Institutes of Health 
guidelines for use and care of animals and the Institutional 
Animal Care and Use Committee (IACUC) at the University 
of Mississippi Medical Center approved all protocols.
Experimental design
Protocol 1
effect of IL-6 on AT1-AA in pregnant rats
We have previously demonstrated a role for IL-6 to induce 
hypertension during pregnancy.8 This experimental protocol 
was performed to determine the role of AT1-AA production 
as a potential mechanism of IL-6 induced hypertension. 
Experiments were performed in normal pregnant rats divided 
into two groups: normal pregnant (NP) rats, n = 6, and chronic 
IL-6 infused NP rats, n = 6. IL-6 (5 ng/day). Recombinant 
rat IL-6 (R&D Systems, Minneapolis, MN) was infused via 
mini-osmotic pumps (model 2002; Alzet Scientific Corpora-
tion, Palto Alto, CA) for 5 days into normal pregnant rats 
during days 14 to 19 of gestation. The previously published 
dose (2.5 ng/day) did not cause the three-fold increase in 
circulating IL-6 and resulted in small increases in MAP.8 
Therefore, in this study we increased the infusion dose in 
order to induce a comparable three-fold rise in circulating 
IL-6 while having a comparable effect on the blood pres-
sure increase as previously reported.8 Carotid catheters were 
inserted on day 18 of gestation and MAP was determined on 
day 19 as described previously.5–8,14–16
Determination of serum IL-6 levels
Colorimetric ELISA (R&D Systems, Minneapolis, MN) was 
used for quantification of serum IL-6 levels. This ELISA kit 
has been modified by the manufacturer since our previous 
publication.8 Inter and intra assay precision was 10.0% and 
8.8%, respectively. This assay displayed a sensitivity level 
of less than 21 pg/mL.
Determination of AT1-AA
Antibodies were detected by the chronotropic responses to 
AT1 receptor-mediated stimulation of cultured neonatal rat 
cardiomyocytes coupled with receptor-specific antagonists 
as previously described.6,14–16 Chronotropic responses were 
measured and expressed in beats per minute (bpm).
Protocol 2
effect of AT1 receptor antagonism on MAP  
in response to IL-6 in pregnant rats
To determine the role of AT1-receptor activation in mediat-
ing IL-6 induced hypertension, two additional groups of 
pregnant rats were used in which IL-6 was infused into 
normal pregnant rats treated with losartan (10 mg/day) in the 
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drinking water. Experiments were performed in two groups of 
rats: NP treated orally with the AT1 receptor antagonist, losar-
tan, NP + L, n = 8, and chronic IL-6 infused NP treated orally 
with the AT1 receptor antagonist, losartan, NP + IL-6 + L, 
n = 6. On day 18 of gestation arterial catheters were inserted 
and MAP was analyzed as described previously.5–7,14–16
statistical analysis
All data are expressed as mean + SEM. Student’s t-test was 
used for comparison of AT1-AA among NP and IL-6 infused 
groups. A value of P , 0.05 was considered statistically 
significant. Statistical analyses were carried out using Prism 
(GraphPad Software, Inc, La Jolla, CA).
Results
Protocol 1
effect of IL-6 on AT1-AA and arterial pressure  
in pregnant rats
As previously shown and repeated here, infusion of IL-6 into 
normal pregnant rats increases mean arterial pressure.8 
 Figure 1 demonstrates that serum IL-6 increases with chronic 
infusion from 63 ± 5 pg/mL to 207 ± 54 pg/mL (P , 0.05). The 
increase in circulating IL-6 was associated with an increase 
in MAP from 102 ± 2 to 118 ± 4 mmHg. In addition, the 
increase in circulating IL-6 was associated with production of 
AT1-AA in pregnant rats. AT1-AA increased  markedly with 
chronic IL-6 (0.7 ± 0.3 bpm NP vs 14.1 ± 1.4 bpm IL-6 NP, 
P , 0.01; Figure 2). In our previous study, IL-6 induced 
hypertension was associated with elevated plasma renin 
activity. Therefore we measured plasma ANGII via HPLC 
in the current study (Wake Forest University) and found it to 
be elevated, albeit, not significantly, with chronic IL-6 infu-
sion (22 ± 2 fmol/mg in NP vs 36 ± 9.5 fmol/mg [P = 0.11] 
in IL-6 infused rats).
Protocol 2
effect of AT1 receptor antagonism on MAP  
in response to IL-6 in pregnant rats
This set of experiments was performed to determine if activa-
tion of the AT1 receptor in response to excess IL-6 during 
pregnancy potentially mediates hypertension. As in the losar-
tan untreated group, infusion of IL-6 increased circulating 
levels of the cytokine from 49 ± 3 pg/mL in NP + L rats to 
212 ± 47 pg/mL (P , 0.05) in NP + IL-6 + L rats Figure 3. 
Although chronic infusion of IL-6 significantly elevated cir-
culating IL-6 in losartan treated pregnant treated rats, chronic 
AT1 R blockade attenuated IL-6 induced hypertension. MAP 
was 85 ± 4 mmHg in NP + L rats vs 85 ± 5 in NP + IL-6 + L 
pregnant rats (Figure 3).
effect of chronic IL-6 and AT1 receptor antagonism 
on pup and placental weights
There were no changes in pup weight in response to chronic 
IL-6 or losartan treatment. Pup weights were 2.4 ± 0.4 g in 
NP rats and were 2.3 ± 0.4 g in IL-6 treated rats. In the losar-
tan treated groups pup weights were 2.1 ± 0.4 g in NP + L 
and were 2.4 ± 0.5 g in NP + IL-6 + L. The only significant 
differences among placental weights were seen between 
NP and NP + IL6 + L groups (P , 0.05). Placental weights 
were 0.61 ± 0.02 g in NP vs 0.52 ± 0.02 g in NP + IL6. In the 
losartan treated group placental weights were 0.55 ± 0.01 g 
in NP + L vs 0.51 ± 0.03 g in NP + IL-6 + L rats. There were 
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Figure 1 Blood pressure, MAP, increases significantly with a three-fold increase in 
circulating IL-6, chronically infused into pregnant rats. 
Note: *P , 0.05.
Abbreviation: MAP, mean arterial pressure.
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Figure 2 AT1-AA, measured by bpm, is stimulated in response to chronic 
IL-6 infusion onto pregnant rats. 
Note: *P , 0.05.
Abbreviations: AT1-AA, agonistic autoantibodies to the angiotensin II type 1 
receptor; IL-6, interleukin-6.
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no major differences in litter size in response to IL-6 infusion 
or losartan treatment among the groups.
Comment
Although preeclampsia is one of the major causes of mater-
nal and perinatal mortality and morbidity, the pathophysiol-
ogy of this disease has yet to be completely understood. The 
initiating event of the disease is associated with abnormal 
cytotrophoblast invasion resulting in inadequate remodel-
ing of the uterine spiral arteries and reduced blood flow 
to the utero-placental unit.1–5 The poorly perfused and 
hypoxic placenta is thought to release factors that result in 
vasoconstriction and hypertension in the mother. Wallukat 
and colleagues were the first to show that preeclamptic 
women develop stimulatory autoantibodies against the 
AT1 receptor.9–12 We previously reported that a reduction 
in placental perfusion is an important stimulus for AT1-AA 
production in pregnant rats.4–6
While AT1-AA are elevated in response to placental 
ischemia, the mechanisms linking placental ischemia and 
AT1-AA production have yet to be fully elucidated.4–16 
It is possible that the generation of AT1-AA in response to 
RUPP is secondary to the increased maternal inflammatory 
response known to be associated with placental ischemia. 
We reported that serum IL-6 is elevated in RUPP rats, and 
infusion of IL-6 into pregnant rats increases arterial pres-
sure and decreases renal hemodynamics.8 In the present 
study, we not only confirm that chronic infusion of IL-6 into 
pregnant rats increases arterial pressure but we also provide 
novel data demonstrating that the hypertension associated 
with IL-6 infusion in pregnant rats results in production of 
the AT1-AA. In addition, there is an important association 
between IL-6 and activation of the endogenous angiotensin II 
system as shown by previous investigators.17–22 These inves-
tigators demonstrated that IL-6 is released from vascular 
 tissue in response to ANGII and that acute, ANGII-dependent 
hypertension is attenuated in IL-6 knockout (KO) mice.21,22 
We have reported that chronic IL-6 increased plasma renin 
activity and here we report that ANGII slightly increased 
with IL-6 infusion while AT1-AA markedly increased. 
However, the results of this study do not distinguish among 
the effects of endogenous ANGII or endogenous AT1-AA to 
mediate the blood pressure effects seen in response to IL-6 
during pregnancy.
While blood pressure and AT1-AA levels are elevated 
in pregnant rats with chronic elevations in circulating 
IL-6, the importance of AT1-receptor activation in causing 
hypertension in IL-6 hypertensive rats is unclear. Therefore, 
a second major objective of our study was to determine 
the importance of AT1-receptor activation in mediating 
the increase in blood pressure in response to chronic IL-6 
excess in pregnant rats. We report in this study that treat-
ment with a selective AT1 receptor antagonist, losartan, 
abolished the hypertensive response to IL-6 during preg-
nancy. Although our findings indicate that AT1 receptor 
activation, in part, contributes to the increase in blood 
 pressure in IL-6 hypertensive rats, our results do not quantify 
the relative importance of the AT1-AA and endogenously 
formed angiotensin II in  activating the AT1 receptor. Future 
studies will be needed to isolate the independent contribu-
tions of endogenous ANG II vs the AT1-AA in activating 
the AT1 receptor when IL-6 is elevated during pregnancy. 
Studies that inhibited either ANGII or AT1-AA production 
during IL-6-induced hypertension are important to further 
elucidate mechanisms mediating hypertension in response 
to elevated IL-6  during pregnancy. However, since ANGII 
is not significantly elevated, and the AT1-AA is markedly 
increased, our interpretation is that the blood pressure 
response could be the result of the AT1-AA activating the 
AT1 R in response to elevated IL-6.
Although the exact mechanism whereby IL-6 stimulates 
the production of AT1-AA remains to be defined, IL-6 is 
known to be a major stimulus for B-cell proliferation and is a 
regulator of various T cell signaling processes.23,24 In rodents 
and humans, polarization and differentiation of autoimmune 
associated CD4 + T helper 17 cells from naïve T helper cells 
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Figure 3 Blood Pressure, MAP, increases in response to a 3-fold increase in 
circulating IL-6, chronically infused into pregnant rats is attenuated in pregnant rats 
treated chronically with losartan.
Note: *P , 0.05.
Abbreviations: MAP, mean arterial blood pressure; IL-6, interleukin-6.
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is dependent upon IL-6. We now know that preeclampsia 
is associated with increased IL-6 and CD4 + T cells.25,26 
 Furthermore our laboratory has recently shown that CD4 + T 
cells are increased in placental ischemic pregnant rats.27 
Adoptive transfer of these CD4 + T cells induced hyperten-
sion and inflammatory cytokines such as TNF alpha, IL-6, 
and sFlt-1 in normal pregnant recipient rats, thereby indicat-
ing the importance of immune cells stimulated in response 
to placental ischemia to cause hypertension and alterations 
in angiogenic factors during pregnancy.27 Further studies 
examining a role for CD4 + T cells to lead to production of 
AT1-AA during pregnancy will be important to further our 
understanding in preeclamptic research.
Although our study shows increases in blood pressure 
in response to IL-6 infusion, this increase is not as dra-
matic as that seen in preeclamptic women. Furthermore 
we see no difference in pup weights between normal 
pregnant rats and those chronically treated either with 
IL-6 or losartan, however, intrauterine growth restriction 
is a common characteristic of preeclampsia. Although the 
IL-6 induced hypertensive pregnant rat model is a good tool 
to examine factors stimulated in response to the cytokine 
during pregnancy, it is not the only factor influencing 
blood pressure or fetal perfusion and growth in response 
to placental ischemia. Identifying factors that may play a 
role in this disease in humans is a driving force for this 
type of research, however, studying mechanisms linking 
hypertension with placental ischemia is obviously limited 
in the hospital patient setting. Therefore, it is important that 
studies are designed to test the importance of endogenous 
IL-6 producing T helper cells to stimulate B lymphocyte 
AT1-AA production and to activate vasoactive mechanisms 
and reduce renal sodium excretory function associated 
with hypertension in response to placental ischemia in the 
pregnant rat. Knowledge gained from these types of stud-
ies in animal models mimicking this disease may lead to a 
better understanding of the pathophysiological mechanisms 
associated with hypertension during preeclampsia. In sum-
mary, these data indicate that IL-6 serves as a stimulus 
of immune mechanisms leading to B cell production of 
AT1-AA and that activation of the AT1 receptor appears 
to mediate hypertension associated with excessive IL-6 
during preeclampsia.
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